Skip to main content
Head for the Cure Foundation
  • About
  • 5K Runs & Events
  • Our Impact
  • In Remembrance
  • News
  • Shop
  • Contact
  • Brains for the Cure
  • Donate
Participate in Our Next Event Donate Online

Head for the Cure Foundation

Donate

Biodexa Pharmaceuticals

About Biodexa Pharmaceuticals PLC

 

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in  aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. 

 

MTX110 is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

  • About
  • 5K Runs & Events
  • Our Impact
  • In Remembrance
  • News
  • Shop
  • Contact
  • Brains for the Cure
  • Donate

Follow Us

Facebook

Twitter

Instagram

Head for the Cure Foundation | 1607 Oak St. | Kansas City, Missouri 64108 | Phone: 816-393-0112 | Contact Us

© 2023 Head for the Cure Foundation